Suresh S. Ramalingam, MD | Authors

January 22, 2020

Suresh S. Ramalingam, MD, discusses how the EGFR tyrosine kinase inhibitor osimertinib compared with other EGFR inhibitors for patients with EGFR-mutant lung cancer.

April 17, 2019

Suresh S. Ramalingam, MD, professor of hematology and medical oncology at the Emory University School of Medicine, discusses the challenge of brain metastases in EGFR-mutated lung cancer and the data surrounding osimertinib (Tagrisso) in this patient population.

August 19, 2014

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the role of heat shock protein 90 (Hsp90) in the treatment of lung cancer.

May 31, 2014

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses data presented at the 2014 ASCO Annual Meeting examining EGFR inhibitors for lung cancer.